# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Benchmark analyst Robert Wasserman reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $8 price target.
Several healthcare stocks associated with mpox are seeing increased attention Thursday after the World Health Organization decl...
A public health emergency for mpox in Africa saw vaccine stocks jump Wednesday. A look at the stocks and what's next for fi...
- Reuters